# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Argus Research analyst Kevin Heal maintains Nasdaq (NASDAQ:NDAQ) with a Buy and raises the price target from $64 to $66.
- Bloomberg
Rosenblatt analyst Andrew Bond downgrades Nasdaq (NASDAQ:NDAQ) from Buy to Neutral and lowers the price target from $76 to $64.
- SEC Filing
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Barclays analyst Benjamin Budish maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and lowers the price target from $76 to $73.